First report of clinical manifestations with suspected immune pathogenesis caused by bromo-acetamide-2-chloro-5-benzophenone (BCB).
D000799:Angioedema / Q000139:chemically induced; D001249:Asthma / Q000139:chemically induced*; D001577:Benzophenones / Q000009:adverse effects*; D003231:Conjunctivitis / Q000139:chemically induced*; D003876:Dermatitis, Atopic / Q000209:etiology*; D004345:Drug Industry; D006801:Humans; D009784:Occupational Diseases / Q000139:chemically induced*; D014581:Urticaria / Q000139:chemically induced
D001577:Benzophenones; C032291:bromoacetamide-2-chloro-5-benzophenone